Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INPHASE: Pyrotinib and Dalpiciclib in HER2+ Advanced Breast Cancer
NCT04095390Phase 2Unknown
- Sponsor
- Shandong Cancer Hospital
- Start
- Sep 2019
- Primary completion
- Nov 2021
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of pyrotinib, dalpiciclib in HER2-positive breast cancer, sponsored by Shandong Cancer Hospital. Status: unknown.
02
Drugs
pyrotinibdalpiciclib
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT04095390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04095390.